Hemogenyx Pharmaceuticals PLC (HEMO) - Total Liabilities
Based on the latest financial reports, Hemogenyx Pharmaceuticals PLC (HEMO) has total liabilities worth GBX3.65 Million GBX (≈ $443.82 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hemogenyx Pharmaceuticals PLC - Total Liabilities Trend (2015–2024)
This chart illustrates how Hemogenyx Pharmaceuticals PLC's total liabilities have evolved over time, based on quarterly financial data. See Hemogenyx Pharmaceuticals PLC short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Hemogenyx Pharmaceuticals PLC Competitors by Total Liabilities
The table below lists competitors of Hemogenyx Pharmaceuticals PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Revolution Beauty Group PLC
LSE:REVB
|
UK | GBX105.86 Million |
|
Cora Gold Limited
LSE:CORA
|
UK | GBX282.00K |
|
Sacks Parente Golf, Inc. Common Stock
NASDAQ:SPGC
|
USA | $2.03 Million |
|
STV Group plc
LSE:STVG
|
UK | GBX190.30 Million |
|
Steppe Cement
LSE:STCM
|
UK | GBX23.90 Million |
|
J Smart Co Contractors PLC
LSE:SMJ
|
UK | GBX22.40 Million |
|
CML Microsystems Plc
LSE:CML
|
UK | GBX14.82 Million |
|
Reliance Industries Limited
IL:RIGD
|
UK | $10.92 Trillion |
Liability Composition Analysis (2015–2024)
This chart breaks down Hemogenyx Pharmaceuticals PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Hemogenyx Pharmaceuticals PLC (HEMO) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -7.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hemogenyx Pharmaceuticals PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hemogenyx Pharmaceuticals PLC (2015–2024)
The table below shows the annual total liabilities of Hemogenyx Pharmaceuticals PLC from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX3.36 Million ≈ $408.58 |
+1.00% |
| 2023-12-31 | GBX3.32 Million ≈ $404.54 |
-13.62% |
| 2022-12-31 | GBX3.85 Million ≈ $468.32 |
+990.88% |
| 2021-12-31 | GBX352.84K ≈ $42.93 |
-80.28% |
| 2020-12-31 | GBX1.79 Million ≈ $217.66 |
+27.88% |
| 2019-12-31 | GBX1.40 Million ≈ $170.21 |
+4.36% |
| 2018-12-31 | GBX1.34 Million ≈ $163.09 |
+408.35% |
| 2017-12-31 | GBX263.69K ≈ $32.08 |
+83.50% |
| 2016-12-31 | GBX143.69K ≈ $17.48 |
-41.78% |
| 2015-12-31 | GBX246.83K ≈ $30.03 |
-- |
About Hemogenyx Pharmaceuticals PLC
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurol… Read more